MUC1 and pachyonychia congenita: Furthermore, the MUC1 peptide-pulsed DC vaccines were used to treat the advanced PC patients and the results indicated that the vaccination is safe and effective to trigger the immunological response to the tumor antigen MUC1 (58, 59).